Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Down 96.6% in February

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 100 shares, a decline of 96.6% from the February 13th total of 2,900 shares. Based on an average daily trading volume, of 10,600 shares, the days-to-cover ratio is currently 0.0 days.

Defence Therapeutics Stock Performance

Shares of DTCFF stock remained flat at $1.00 during trading hours on Friday. The stock had a trading volume of 1,500 shares, compared to its average volume of 20,078. Defence Therapeutics has a 52 week low of $0.27 and a 52 week high of $1.32. The stock’s 50 day moving average is $0.73 and its two-hundred day moving average is $0.52.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.